Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian life sciences company leading in photodisinfection-based therapies to prevent and treat a broad spectrum of infections, including drug-resistant pathogens. Their platform technology, known as antimicrobial photodynamic therapy (aPDT), destroys pathogens rapidly without causing resistance. The company focuses on developing and commercializing novel antimicrobial therapies that address significant patient needs, are environmentally safe, and cost-effective. Their lead product, Steriwave™, is a nasal decolonization therapy that eradicates pathogens in minutes, significantly reducing healthcare-associated infections and surgical site infections. Ondine's technology is also under development for other applications such as treatment of chronic rhinosinusitis, burns, wounds, disinfection of endotracheal tubes, ventilator-associated pneumonia, and combating antimicrobial resistance.
Industries
Nr. of Employees
small (1-50)
Ondine Biomedical Inc.
Vancouver, British Columbia, Canada, North America
Products
Nasal photodisinfection system (nasal decolonization device)
A clinical device and procedure that administers a topical photosensitizer to the nostrils followed by targeted red-light illumination to rapidly reduce nasal pathogens in a short clinical session.
Pipeline topical antiviral and expanded photodisinfection applications
Development programs to extend topical photodynamic applications to reduce viral load in the upper respiratory tract and to address clinical use cases such as chronic rhinosinusitis, wound and burn decolonization, and endotracheal tube decontamination.
Nasal photodisinfection system (nasal decolonization device)
A clinical device and procedure that administers a topical photosensitizer to the nostrils followed by targeted red-light illumination to rapidly reduce nasal pathogens in a short clinical session.
Pipeline topical antiviral and expanded photodisinfection applications
Development programs to extend topical photodynamic applications to reduce viral load in the upper respiratory tract and to address clinical use cases such as chronic rhinosinusitis, wound and burn decolonization, and endotracheal tube decontamination.
Services
On-site demonstrations and clinical deployment support
Operational demonstrations of the nasal photodisinfection procedure and support for adoption including presentations, training and on-site implementation assistance for healthcare teams.
Regulatory and clinical program management
Organizational management of regulatory submissions, clinical study coordination and liaison with regulatory authorities to support clinical trials and market access.
Health economic and implementation study support
Collaborative economic analyses and implementation studies to estimate institutional cost savings and operational impact from adoption of decolonization protocols.
On-site demonstrations and clinical deployment support
Operational demonstrations of the nasal photodisinfection procedure and support for adoption including presentations, training and on-site implementation assistance for healthcare teams.
Regulatory and clinical program management
Organizational management of regulatory submissions, clinical study coordination and liaison with regulatory authorities to support clinical trials and market access.
Health economic and implementation study support
Collaborative economic analyses and implementation studies to estimate institutional cost savings and operational impact from adoption of decolonization protocols.
Expertise Areas
- Antimicrobial photodynamic therapy
- Nasal decolonization and perioperative infection prevention
- Clinical trial execution and hospital pilot deployment (including Phase 2/3)
- Medical device development and design transfer for optical/photonic systems
Key Technologies
- Antimicrobial photodynamic therapy (aPDT)
- Photosensitizer chemistry for topical antimicrobial use
- Red-light activation using laser, LED or fiber-optic delivery
- Optical waveguide and targeted light-coupling engineering